Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, inflammatory diseases, infectious diseases, and cancer. Its proprietary SNAP-TI platform promotes immune tolerance by modulating T cell responses, while viral vector platforms (ChAdOx and MVA) induce robust CD8+ T cell immunity. The company’s pipeline includes candidates for celiac disease, chronic hepatitis B, HPV, and various cancers, leveraging advanced antigen design and delivery technologies.
This description was generated via AI from an annual report. Updated about 1 year ago.